Patient-identified most bothersome symptom in preventive migraine treatment with eptinezumab: A novel patient-centered outcome.

ABSTRACT:

Objectives

To describe the methodology and implications of the patient-identified most bothersome symptom (PI-MBS) measure used in the phase 3, multicenter, randomized, double-blind, placebo-controlled, and parallel-group PROMISE-2 trial and to evaluate the contribution of this measure to the assessment of the preventive migraine benefits of treatment.

Background

Although freedom from MBS is a coprimary endpoint in acute migraine treatment trials, its evaluation in preventive migraine trials is limited. The PROMISE-2 study assessed a unique PI-MBS measure as a secondary endpoint.

Methods

This was a secondary analysis of data from the PROMISE-2 study. Adults with chronic migraine (CM) were randomized to receive intravenous (IV) eptinezumab 100 mg, eptinezumab 300 mg, o

SUBMITTER: Lipton RB 

PROVIDER: S-EPMC8251621 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature